Chikungunya Vaccine Advance, but experts say that it is necessary to expand the target audience for overall protection | Health
Afterwards Approval And and The first Chikungunya vaccine National Health Survivalence Agency (Anvisa), The Ministry of Health has announcedThis is Tuesday. The virus was identified in Brazil in 2014 and now all states have confirmed cases. Until April 14 this year, the country added 68.1 thousand illnesses, killing 56 people. In para, they were registered 369 cases of disease 39 in 2024 and 2025, without death. According to the infectologist Alessandre Guimaries, vaccinated against arboviruses such as Domunia, Dengue and Zika, broadcast by the Agypti of mosquitoes, still reaching one Limited by the Public AgeIt makes the other Preventive measuresAs the removal of mosquito spread. He also pointed out the challenges of developing the Zika virus vaccine.
The vaccine against Chikungunya is made of a single dose, attenuated re -OMB complexion, and weak living viruses. It is in danger of being exposed to more than 18 people, except for individuals who are developed by Austrian Pharmaceutical Walneva, pregnant women and immunity. The Immunizer was initially produced by IDT Biolazica GMBH in Germany, which was scheduled for future manufacture in Brazil by the Butanton Institute.
The National Technology Incorporation Commission (Konitech) assesses the request to include the Chikungunya vaccine in the SUS, but the analysis does not expire.
Vaccine has not yet been guaranteed to control arbovirus control
It is still fast to say that vaccines can control arboviruses such as Chikungunya and Dengue, and SEPA is currently available for 10 to 14 years old. “To control these arboviruses, a set of preventive measures is fundamentally necessary,” especially the struggle against the spread of Ides Aegipti, the use of mosquitoes, window screens and broadcasting ill -people.
Guimaris believes that despite the vaccination, the basic, is still offering to limited age in Brazil, which prevents adequate population coverage. In this scenario, “personal, personal action, at home, becomes very important”, as well as public policies targeting basic sanitation and social and environmental actions.
To reach a more effective control over country diseases, it is necessary to expand the age of vaccine and at the same time, to maintain and intensify measures to deal with the vector. Warning is imperative: By 2024, Brazil is concentrated from 30% to 40% of Chikungunya cases worldwide, which divides the earthquake state of the disease with India.
Single dosage provides advantage of vaccine
In addition to the high impact, the simplicity of the single dose scheme is more beneficial in terms of chikungunya vaccine synthesis and population range, compared to dengue vaccine, two doses are required to achieve a total of 90% effect against the severe forms of the disease.
“Since most people only attend health facilities, complete the single -Motadu vaccine scheme significantly increases the coverage and accelerates mass protection. In addition, studies show the high efficiency of the Chikungunya vaccine: 98.9% of antibody production, with permanent results, in Brazilian
Challenges for zika virus vaccine
Although Dengue, Chikungunya and Zika are broadcasting Aedis Aegipti, there is no vaccine accepted against the Zika Vishnu. According to Para Registered, SESPA, 30 Zika cases in 2024, without deaths, and no case so far in 2025.
According to Guimaries, the challenge is that the challenge is no longer in circulation, which makes it difficult to conduct efficiency and security studies, especially 3. It is “it will have too many costs in this research” and still not enough to maintain the ability of scientists in Brazil.
Currently, there are two foreign vaccines on Zika during the clinical testing phase: one in one phase 1, which assesses security and in the other, analyzes the antibody production. In Brazil, the Buttanton Institute conducts prelinical studies. The doctor also emphasizes the importance of the national product of immunity, as the “nationalism of the vaccine means the cost of production”, which facilitates the expansion of the target audience after the supply growth and the approval of the supply.
Dengue Immunization
Brazilian became the first country to be provided by Dengue Vaccine through a public health system in February 2024. Produced by the Takeda Japanese laboratory, this vaccine lives in municipalities with 10 to 14 years of age and over 100,000 cabinet and high incidents in adolescents. The vaccine scheme has two doses with a three -month interval.
According to SESPA data, in 2024, Para recorded 17,578 cases and 12 dengue deaths. By 2025, there were 5,410 cases and 9 deaths till March 31. He received 79,909 doses of vaccination against the disease, up to April 2025 and Para 22 municipalities. In 2024, 30,603 doses (11% coverage) were applied, and in 2025, in April 14, 10,841 dose (3.88% coverage), 41,444 doses from 2024, vaccinated 14.84%. The Secretariat emphasized that the implementation of the vaccine was the responsibility of the municipalities.
